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Abstract
Background: An increasing number of publications are suggesting that galectin-3 (Gal-3) and soluble cadherin
fragments, such as E-cadherin (sE-CAD) and N-cadherin (sN-CAD), may be considered as cancer markers. Despite
the promising results of the studies, there are no data concerning their levels in the plasma of echinococcosis
patients. In most cases, echinoccocosis affects the liver, and its symptoms and disease course are very similar to
those of liver cancer. The aim of the present study was to observe whether echinococcosis affects the
concentration of soluble sN-CAD, sE-CAD fragments and Gal-3 in plasma and to determine which of them could
be considered reliable liver cancer markers for further research.
Methods: The concentrations of sN-CAD, sE-CAD and Gal-3 in the EDTA plasma of patients suffering from
echinococcosis (N=2 0 ), liver cancers (N=1 0 ) and healthy subjects (N=2 0 ) were measured using the ELISA
method.
Results: The plasma concentration of sE-CAD was lower (p = 0.0381), and that of Gal-3 higher (p = 0.0288), in
echinococcosis than in the healthy group. However, only the concentration of sE-CAD differed significantly among
the three analysed groups. In echinococcosis there was a correlation between the sE-CAD and CRP levels (rs = 0.79;
p = 0.0066) as well as a correlation between the sE-CAD level and the number of leukocytes (rs = 0.65; p = 0.0210)
in the blood.
Conclusions: Echinococcosis affects the concentration of soluble sE-CAD fragments and Gal-3 in plasma. sE-CAD
can be considered as a marker for differentiation between liver cancer and echinoccocossis, a parasitic liver disease
similar in symptoms. Further study is required to confirm these preliminary results.
Virtual Slides: The virtual slide(s) for this article can be found here:
http://www.diagnosticpathology.diagnomx.eu/vs/2115657402650448.
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Background
Echinoccocosis is a parasitic disease caused by a cestode
belonging to the genus Echinococcus. The most impor-
tant species for medical purposes are E. granulosus (cys-
tic echinococcosis) and E. multilocularis (alveolar
echinococosis). The liver is the most commonly invaded
organ (the liver and the lungs represent more than 90%
of reported cases). Pathological symptoms such as
abdominal pain and/or jaundice are caused by the pres-
sure the enlarged cyst exerts on the liver tissue. There is
a d d i t i o n a l l yap a l p a b l em a s si nt h eh e p a t i ca r e a[ 1 ] .
Similar symptoms are registered in patients with liver
cancer. Moreover, echinococcosis and liver cancer have
a long asymptotic occurrence. Cystic echinococcosis is
usually easy to diagnose using an ultrasound image. It
is, however, occasionally difficult to distinguish it from
other liver tumours. In these cases, other diagnostic
tools, such as serological tests, are used. False positive
or false negative reactions, however, may still occur [2].
Moreover, echinococcosis is sometimes not considered
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the two diseases. An erroneous diagnosis of a cyst as
being a cancer is associated with the risk of its being
damaged during surgery. This can result in anaphylactic
shock. Proper cancer markers should therefore be able
to distinguish between the cancer and the parasitic cyst.
An increasing number of publications are suggesting
that galectin-3 (Gal-3) and soluble cadherin fragments,
such as E-cadherin (sE-CAD) and N-cadherin (sN-
CAD), may be considered as cancer markers. Although
the concentration of proper cancer markers should not
only distinguish between healthy and cancerous subjects,
but also between cancerous subjects and those suffering
from other tumour progression diseases such as echino-
coccosis, there are no data concerning sE-CAD, sN-
CAD and Gal-3 levels in the plasma of echinococcosis
patients. This disease may sometimes be misdiagnosed
as cancer, which can result in patient death.
T h ea i mo ft h ep r e s e n ts t u d yw a st oo b s e r v ew h e t h e r
echinococcosis affects the concentration of soluble sN-
CAD, sE-CAD fragments and Gal-3 in plasma and to
determine which of them are suitable for further
research as reliable liver cancer markers.
Methods
Materials
Mouse anti-N-cadherin antibodies and 3,3’,5,5’-Tetra-
methylbenzidine (TMB) solution for ELISA were pur-
chased from Sigma-Aldrich (Poznan, Poland). Goat anti-
mouse antibodies conjugated with horseradish peroxi-
dase were supplied by Jackson ImmunoResearch Labora-
tories (Biokom, Janki, Poland). Recombinant Human N-
Cadherin/Fc Chimera and Quantikine Human sE-Cad-
herin Immunoassay were obtained from R&D Systems
(Biokom, Janki, Poland). The Gal-3 ELISA kit was pur-
chased from BioVendor R&D (Biokom, Janki, Poland)
and the hs-CRP kit from Demeditec Diagnostic (Bio-
kom, Janki, Poland).
Ethics
This study was approved by the Polish Research Ethics
Committee (KB 32/2011).
Apparatus
Photometric measurements were performed using a Bio-
Tek Synergy 5 spectrophotometer (Biokom, Janki,
Poland).
Plasma collection
EDTA-plasma samples were obtained from healthy
volunteers (n=2 0 ) and from subjects suffering from
cystic echinococcosis (n=2 0 )a sw e l la sp r i m a r y( h e p a -
tocellular carcinoma, cholangiocarcinoma) and
secondary (metastatic adenocarcinoma of the colon and
metastatic endometrial cancer) liver cancer (n=1 0 ),
treated at the Warsaw Hospital for Infectious Diseases
and at the Czerniakowski Hospital, Medical University
of Warsaw. Plasma samples were separated from blood
within 1 to 3 h after blood collection and separated by
centrifugation at 2500 rpm for 30 min at about 10°C.
The separated samples were stored at -70°C until being
assayed.
ELISA methods
The concentration of sE-CAD, Gal-3 and hs-CRP in
plasma was determined by sandwich ELISA using com-
mercially available kits. As no commercially available kit
to measure plasma sN- CAD concentration was avail-
able, measurements were performed using the procedure
reported by Derycke for direct ELISA [3]. The ELISA
plates were coated with twice-diluted plasma overnight.
Mouse monoclonal anti-N-cadherin antibodies (1:200)
were the primary antibody and goat anti-mouse antibo-
dies conjugated with horseradish peroxidase (1:5000)
were the secondary antibody. TMB was used as a sub-
strate. The absorbance was recorded at 450 nm, with
the correction wavelength at 620 nm, after the reaction
was quenched with an acidic solution (2 M aq. HCl).
Statistical analysis
Normal distribution and variance homogeneity of the
data (before and after the variables had been trans-
formed into their natural logarithms) were checked
using the Shapiro-Wilk test and Leven’s test, respec-
tively. When the data were not normally distributed or
their variance not homogeneous (p < 0.05), the statisti-
cal significance evaluation was performed using the
Kruscal-Wallis test. Otherwise, the ANOVA test was
used. The correlations between the variables were ana-
lyzed using Spearman’s rank correlation test, and
expressed as rs (correlation coefficient) and p (p < 0.05
were described as significant). Discriminant function
analysis was used to determine which variables discrimi-
nate between the examined groups. The classification
functions were used to predict a categorical dependent
variable by one or more variables. Each function gives
the formula according to which the classification scores
for the analyzed case can be calculated as follows:
Si=ci+wi1 × x1 + wi2 × x2 + ...+ wim × xm
where: si -is the score for i’t hg r o u po f1 , 2 ... m vari-
ables; ci-constant for the i’th group; wi1...wim-discrimi-
nant function coefficients.
Each case is classified into the group with the highest
score. Calculations were performed using STATISTICA
version 9.1 software.
Giebultowicz et al. Diagnostic Pathology 2012, 7:17
http://www.diagnosticpathology.org/content/7/1/17
Page 2 of 5Results
Analyzed group features
The mean CRP level was 5.0 (7.3) mg/dl in the cancer-
ous patients and 4.9 (5.5) mg/dl (p = 0.59;N S )i nt h o s e
suffering from echinococcosis. Their leucocytes levels
were 10.5 (3.8) and 5.3 (1.6) K/μl( p = 0.0022), respec-
tively. The mean age was 64 yrs (range 38-79) in the
cancerous group, 48 yrs (range 21-75) in the echinococ-
cosis group, and 41 yrs (range 28-65) in the control
group. Occurrence of Echinococcosis was confirmed
using ultrasound imaging and serological tests. Cancers
were confirmed histopathologically.
sN-CAD concentration
A v e r a g ep l a s m ac o n c e n t r a t i o no fs N - C A Di nt h ee x a m -
ined groups is summarized in Table 1. Post-hoc testing
revealed that the sN-CAD concentration in the plasma
of healthy subjects was significantly higher than in the
plasma of echinococcosis (p = 0.0019) and liver cancer
(p < 0.00001) patients. The difference between the sN-
CAD level in echinococcosis and liver cancer was not
significant (p = 0.26). There was also no statistically sig-
nificant correlation between sN-CAD and CRP levels or
between the sN-CAD level and the number of leuko-
cytes in the examined groups.
sE-CAD concentration
Average plasma concentration of sE-CAD in the exam-
ined groups is summarized in Table 1. Post-hoc testing
revealed that the sE-CAD concentration in the plasma
of cancerous subjects was significantly higher than in
t h ep l a s m ao fe c h i n o c o c c o s i s( p = 0.0001)p a t i e n t sa n d
healthy subjects (p = 0.0381). Moreover, in echinococco-
sis, there was a correlation between the sE-CAD and
CRP levels (rs = 0.79; p = 0.0066)a sw e l la sac o r r e l a -
tion between the sE-CAD level and the number of leu-
kocytes (rs = 0.65; p = 0.0210) in the blood.
Gal-3 concentration
Average plasma concentration of Gal-3 in the examined
groups is summarized in Table 1. Post-hoc NIR testing
revealed that the Gal-3 concentration in the plasma of
echinococcosis patients was higher than that in the
plasma of healthy subjects (p = 0.0211) and cancerous
patients (p = 0.1151, NS). There were no significant dif-
ferences between the concentration of Gal-3 in the
plasma of cancerous and healthy subjects (p = 0.65, NS).
There was also no statistically significant correlation
between Gal-3 and CRP levels or between the Gal-3
level and the number of leukocytes in the examined
groups.
Discriminant analysis
Discriminant function analysis showed that by involving
data such as the plasma concentration of Gal-3 and sN-
CAD, 100% of healthy cases, 71% of echinococcosis
cases, and 67% of liver cancer cases could be correctly
classified.
The test of dimensionality for discriminant analysis
indicated that only the first dimension was statistically
significant (p = 0.00001). The standardized canonical
discriminant function coefficients were -1.06 for sN-
CAD and 0.58 for Gal-3 plasma concentration. The
mean canonical roots were -1.44 for the healthy sub-
jects, 0.31 for the echinococcosis patients and 1.13 for
t h ec a n c e rp a t i e n t s .T h ec l a s s ification function coeffi-
cients are summarized in Table 2.
Discussion
Galectin-3 is reported to be overexpressed in a variety of
neoplastic cells and is suggested to be involved in
tumour metastasis by, e.g. enhancing adhesion between
tumour cells and extracellular matrix, promoting embo-
lization. However, no generalized conclusion on the role
of Gal-3 in cancer has yet been established. The lectin is
not only produced and secreted into the plasma by
tumour tissues, but also by peritumoural inflammatory
cells and stromal cells.
Elevated Gal-3 levels in the serum/plasma have been
reported in some cancers, e.g., metastatic breast and
gastrointestinal cancer. However, decreased levels of this
lectin have been observed in metastatic breast, endome-
trial and ovary carcinomas, while the levels in Non-
Hodgkin’s lymphoma and melanoma [4] have not been
observed to change. Elevated levels of circulating Gal-3
have not only been observed in cancers, but also in
chronic inflammations, e.g. inflammatory bowel disease
[5], obesity, type 2 diabetes [6], and heart failure [7,8].
Table 1 Average values (mean, median) and dispersion (standard deviation, interquartile range) of soluble N-cadherin,
E-cadherin and galectin-3 concentration in the plasma of the examined group
Concentration [ng/ml] Echinococcosis (n = 20) Cancer (n = 10) Healthy (n = 20)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
sN-CAD 94 (40) *
H 80 (23) 58 (47) *
H 50 (70) 141 (11) *
EC 146 (12)
sE-CAD 9 (11) 6.5 (3.2)*
CH 12.4 (4.6) 11.0 (1.5) *
EH 8.6 (1.4) 8.4 (2.0) *
EC
Gal-3 12.5 (6.0)*
CH 10.4 (8.8) 9.9 (2.7)*
E 9.1 (4.1) 9.1 (1.5)*
E 9.8 (2.3)
*- statistically significant differences (p < 0.05) between the examined groups (E-echinoccocosis, C-cancer, H-healthy)
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Gal-3 concentration was observed in liver cancer (NS)
and echinococcosis patients than in the healthy control
group. The results concerning the cancerous patients,
even if not significant, seem to be consistent with the
results mentioned above [4] as well as with those
reported by Matsuda et al. [9], who observed a higher
level of the circulating lectin in liver cancer than in the
control group and subjects with chronic liver disease.
However, the present report would seem to be the first
to compare the levels of Gal-3 in the plasma of cancer
patients, echinoccosis patients and healthy volunteers.
The highest level observed in echinococcosis could be
the result of inflammation related to parasite invasion.
Nevertheless, liver cancer is also associated with inflam-
mation and exhibited similarC R Pl e v e l st o ,a n dh i g h e r
leukocyte levels than, echinococcosis. Factors other than
the inflammation that occurs in echinococcosis might
therefore influence the Gal-3 level in the plasma.
sE-cadherin is a form, cleaved from E-cadherin by
proteases such as MMP-3, MMP-7 [10], plasmin [11],
ADAM10 [12], ADAM15 [13], whereas sN-CAD is
cleaved by ADAM10 [14], MT1-MMP [15], MT5-MMP
[16], MMP-9, MMP-12 [17], and Presenilin 1 [18]. The
induction/upregulation of v a r i o u sM M P s( e . g .M M P - 2 ,
MMP-3, MMP-7 and/or MMP-9) has been detected in
tumourous liver tissues obtained from, e.g. hepatocellu-
lar carcinoma (HCC) patients, whereas the expression of
plasminogen activators appears to be largely confined to
stromal and inflammatory cells. Inflammation also
enhances the expression of MMPs, e.g. in endothelial
cells, lymphocytes and macrophages. Furthermore, the
expression of certain MMPs and plasminogen activators
is also increased in liver cells during liver regeneration
[19,20].
Elevated sE-Cad was observed in the serum or plasma
of patients with gastric carcinoma [21], bladder cancer
[22], non-small cell lung cancer [23], melanoma [24],
late-stage colorectal carcinoma [5], and hepatocellular
carcinoma [25]. However, higher levels of that cadherin
have also been found in gastroesophageal reflux disease
[26], multiorgan dysfunction [27], endometriosis [28],
familial adenomatous polyposis [25], and acute pancrea-
titis [29]. Higher amounts of the serum sN-CAD have
been described in a group of cancerous patients suffer-
ing from prostate carcinoma, breast cancer, ovarian
cancer, and gastrointestinal carcinoma, and have been
mentioned as being present in diabetes and liver cirrho-
sis (data not shown) as well [3]. The present study
exhibited a higher plasma concentration of sE-CAD in
the liver cancer group than the healthy group. This is
consistent with the results reported by Sayoma et al.
[25].
Moreover, the level of the marker was observed to be
lower in the echinococcosis group than the healthy
control group. This suggests that sE-cadherin would be
a valuable marker of HCC not only because of its asso-
ciation with early recurrence and extrahepatic metasta-
sis [25], but also owing to its ability to distinguish
between liver cancer and echinococcosis. In the pre-
sent study, the plasma sN-CAD concentration in liver
cancer was also observed to be lower than that in the
healthy group. These results are difficult to explain
and require further analysis. Moreover, they seem to
be inconsistent with the results reported by Derycke et
a l .[ 3 ] .H o w e v e r ,t h e r ei sn oi n f o r m a t i o na b o u tt h ep r e -
sence of liver carcinoma in the cancerous group exam-
ined by them.
The lower levels of the plasmas sN-CAD and sE-CAD
in echinococossis patients than in healthy subjects could
be explained by the ability of Echinococcus granulosus to
evade certain defence mechanisms by such means as
modulating the host’s immune system and resisting the
host’s proteolytic enzymes by dealing efficiently with, e.
g. MMP-9 [19,30]. Discriminant analysis revealed that
the association of two or more markers significantly
increased their efficiency. These results seem to encou-
rage other scientists to combine two or more markers,
which are not effective enough when used separately.
Conclusions
Echinococcosis affects the concentration of soluble sE-
CAD fragments and Gal-3 in plasma. sE-CAD can be
considered as a marker for differentiating between liver
cancer and echinoccocossis, a parasitic liver disease
similar in symptoms. Further study is required to con-
firm these preliminary results.
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